Comparison of the effectiveness of antibody and cell-mediated immunity against inhaled and instilled influenza virus challenge

Katie Rivers1, Larry E Bowen2,3, Jin Gao1, Kevin Yang1, John E Trombley2, J Kyle Bohannon2 and Maryna C Eichelberger1*

Abstract

Background: To evaluate immunity against influenza, mouse challenge studies are typically performed by intranasal instillation of a virus suspension to anesthetized animals. This results in an unnatural environment in the lower respiratory tract during infection, and therefore there is some concern that immune mechanisms identified in this model may not reflect those that protect against infectious virus particles delivered directly to the lower respiratory tract as an aerosol.

Method: To evaluate differences in protection against instilled and inhaled virus, mice were immunized with influenza antigens known to induce antibody or cell-mediated responses and then challenged with 100 LD50 A/PR/8/34 (PR8) in the form of aerosol (inhaled) or liquid suspension (instilled).

Results: Mice immunized with recombinant adenovirus (Ad) expressing hemagglutinin were protected against weight loss and death in both challenge models, however immunization with Ad expressing nucleoprotein of influenza A (NP, or M2 resulted in greater protection against inhaled aerosolized virus than virus instilled in liquid suspension. Ad-M2, but not Ad-NP-immunized mice were protected against a lower instillation challenge dose.

Conclusions: These results demonstrate differences in protection that are dependent on challenge method, and suggest that cell-mediated immunity may be more accurately demonstrated in mouse inhalation studies. Furthermore, the data suggest immune mechanisms generally characterized as incomplete or weak in mouse models using liquid intranasal challenge may offer greater immunity against influenza infection than previously thought.

Keywords: Influenza, Aerosol, Inhalation, Instillation, Mouse, Antibody, CD8+ T cell, Immunity

Background

Annual influenza epidemics result in approximately 40,000 deaths in the USA and at least one million deaths worldwide [1,2]. Vaccination provides protection against illness when the antigens in inactivated split vaccines are antigenically-matched to the circulating influenza viruses, reflecting the activity of antibodies that neutralize virus infectivity and limit virus spread. Both hemagglutinin (HA) and neuraminidase (NA)-inhibiting antibodies are independent correlates of immunity [3]. However, cell mediated immunity contributes to virus clearance, with the number of IFN-γ secreting T cells correlating with the efficacy of live, attenuated influenza vaccine in children [4].

Efforts are currently being made to develop universal influenza vaccines that offer broad protection by using target antigens that are conserved across influenza A subtypes: these antigens include nucleoprotein (NP), Matrix (M), the conserved stem region of HA, neuraminidase (NA), and M2. Several publications show that adenovirus (Ad) provides a suitable vector for delivery of M2 and NP antigens [5-8]. Adenovirus expressing M2 is known to induce high M2-specific antibody titers that bind to a highly conserved region of M2 that is extracellular (M2e) as well as T cell
responses in BALB/c mice. However, antibody responses are sufficient to protect against challenge with PR8 [9]. These antibodies do not act alone, relying on FcR + NK cells to kill the M2-expressing infected cells [10]. Immune responses to NP expressed by recombinant adenovirus include both antibody and CD8+ T cell responses, with the NP-specific CD8+ T cells and not antibodies contributing to virus clearance. While the lung parenchyma contains some NK [11] and memory T cells [12], these cell types are recruited in substantial numbers from the circulation. Recruitment is a response to chemokines produced by infected cells or activated macrophages – NK cells migrate toward a variety of soluble mediators expressed at infected or inflammatory sites (reviewed in [13]) and there is evidence that IL-15 is responsible for recruitment of influenza-specific CD8+ T cells to the infected lung [14].

The animal models used in preclinical studies of these vaccines include mice, guinea pigs and ferrets [15-17]. These animal models typically utilize an intranasal or intratracheal route of virus challenge, with virus delivered in a liquid suspension to anesthetized animals so that natural reflexes to swallow or sneeze are avoided. The volume administered is substantial, ensuring that virus is deposited in the lower respiratory tract. This large challenge volume is likely to impact normal lung physiology, infection kinetics, and that for direct deposition in the lower respiratory tract, aerosol particles < 2 μm mass median aerodynamic diameter, and determined the LD_{50} of mouse-adapted A/PR/8/34 (PR8) delivered under these conditions [26]. We demonstrated that approximately 10-20 fold less aerosolized virus results in death than instilled virus, a difference previously noted by others [27]. In this study we compare the ability of different vaccination strategies to protect mice against a lethal dose of inhaled and instilled influenza virus.

**Results and discussion**

Immunization with live virus and recombinant adenovirus (Ad) expressing influenza proteins

BALB/c mice were exposed intranasally to a sublethal dose of PR8 (H1N1) or a heterologous reassortant H3N2 virus X-31, or vaccinated intramuscularly with recombinant adenovirus (Ad) expressing HA, M2, and NP of influenza A viruses (Ad-NP_{A}), or NP of influenza B viruses (Ad-NP_{B}). The latter vaccine group as well as naïve mice served as negative controls since these mice should not be protected against challenge with PR8. Three weeks after vaccination, the mice were bled and hemagglutination inhibition (HAI) antibody titers measured. Mice immunized with Ad-HA, but not Ad-M2 or Ad-NP had HAI titers of approximately 1:100 showing that this vaccination strategy is effective at inducing an antibody response. The capacity of Ad-M2 and Ad-NP to induce M2-specific antibodies and NP-specific CD8+ T cells, has been established by others using these same recombinant adenovirus preparations [5,6,28]. HAI antibodies reactive with PR8 were also present in the sera of mice exposed to sublethal dose of PR8 (HAI titers of approximately 1:600), but not following X-31 (H3N2) exposure. As others have reported, NP-specific CD8+ T cells are activated after live influenza A virus infection, and are recruited in substantial numbers to the lungs following challenge with virus that is of a different subtype [29].

Virus replication in the lungs of vaccinated mice is similar 4 days after inhaled and instilled PR8 challenge

Five weeks after virus exposure or vaccination, equal numbers of mice (n = 10) in each vaccine group were exposed to PR8 as an inhaled aerosol or as an instilled liquid suspension. Aerosol challenge was conducted as described in Methods and Materials, using a nose-only exposure.
system without sedating the mice. In contrast, instillation was conducted by placing drops of a virus suspension onto the nares of anesthetized mice. The same lethal dose (100 LD₅₀) was used; since BALB/c mice die when 10-fold lower amount of PR8 is inhaled compared to intranasal instillation [26], the amount of virus used in the inhalation challenge was approximately 10-fold less than in the instillation challenge.

Five mice in each group were sacrificed 4 days after challenge and lungs removed for virus titration; the clinical signs of disease and mortality were monitored in the remaining animals. These results show similar amounts of virus in the lungs of challenged mice, regardless of the challenge method (Figure 1). At this time point, virus was not detected in the lungs of mice previously exposed to PR8 or vaccinated with rAd-HA. There was a significant reduction in lung virus titers for mice previously exposed to the heterologous X-31 virus, providing evidence that heterosubtypic immunity induced by previous live virus infection, provides similar protection against inhaled and instilled virus. However, immunization with Ad-M2 and Ad-NP₂ did not reduce day 4 virus titers after either inhalation or instillation.

Complete immunity against both inhaled and instilled influenza in mice previously exposed to live homologous or heterologous virus, or vaccinated with Ad-HA

Mice that had previously been exposed to infectious PR8 or that had been immunized with rAd-HA had no virus in their lungs 4 days after either inhalation or instillation of 100 LD₅₀ of the homologous virus (Figure 1). Not only were these mice protected from infection, they were fully protected against weight loss (Figure 2) and death (Figure 3). This protection correlates with the presence of HA inhibiting antibodies that are known to neutralize virus infectivity.

Although some virus replication was measured in the lungs, mice previously exposed to heterologous live X-31 virus were completely protected against weight loss (Figure 2) and death (Figure 3) after both inhaled and instilled virus challenge. These mice did not have antibodies that inhibit either HA or NA activities of the challenge virus, PR8 (not shown). As reported in numerous studies of heterologous protection, this protection is usually mediated by influenza-specific CD4+ and CD8+ T cells that kill infected cells [5,29], although antibodies to conserved antigenic epitopes, such as M2e, may also contribute to heterosubtypic immunity [9,30,31].

Immunity against inhaled but not instilled influenza in mice vaccinated with recombinant Ad-M2 or Ad-NP₂

Ad-M2, Ad-NP₂, and Ad-NP₂-immunized mice lost weight at the same rate as the naïve mice after challenge with a liquid suspension of PR8 (Figure 2). These groups of mice all died by day 8 post-challenge (Figure 3). Interestingly, this was one day later than the challenged naïve mice died, suggesting some benefit of the Ad-M2, Ad-NP₂ and Ad-NP₂ immunizations. In contrast, weight loss after aerosol challenge of the Ad-M2 and Ad-NP₂-immunized mice slowed 3 days after aerosol challenge, although their weights remained significantly less than the Ad-HA group (p < 0.001, two-way repeated measures ANOVA) and neither group regained all weight by day 10 post-challenge. The M2-immunized mice were partially protected from this aerosol challenge, with survival of 4 of 5 mice whereas all the naïve mice succumbed to infection by day 8 post-inhalation challenge. Survival between Ad-NP₂-immunized and Ad-M2 or Ad-NP₂-immunized mice was not different, but trended towards significance (p = 0.054). As noted for challenge with instilled virus, immunization with Ad-NP₂ provided a small but consistent benefit, with 1 of the 5

![Figure 1 Comparison of virus titers in the lungs of vaccinated mice after instillation and inhalation PR8 challenge.](image-url)
Ad-NPB-immunized mice surviving aerosol challenge. Repeat experiments with larger numbers of mice per group are needed to verify the significance of these findings.

Since the mice used in this study were from the same birth cohort and immunized with the same vaccine preparations at the same location and time, differences in protection against instilled and inhaled virus could reflect differences in virus load and/or differences in the capacity of the immune response to protect these different challenge conditions. In mice, lung virus titers are usually not reflective of input dose and therefore we were not surprised by the similar virus loads measured 4 days after challenge with inhaled and instilled virus (Figure 1). However, since the LD₅₀ of inhaled virus was 10-fold less than the instilled virus, the number of infectious particles (approximately 870 vs 5160 PFU/mouse [26]) was clearly different and therefore an additional experiment was conducted to test whether the initial dose explained the difference in protective capacity. Ad-M2 and Ad-NPₓ-immunized mice were therefore challenged by intranasal instillation with similar total infectious units of PR8 as had been inhaled. This amount of virus was therefore equivalent to 10 LD₅₀ in the instillation model.

This experiment included a group challenged by instillation with 100 LD₅₀ PR8, repeating the first experiment. Weight loss and survival of groups challenged with 100 LD₅₀ PR8 were the same as noted previously. As for this high challenge dose, the mice immunized with Ad-HA were fully protected against virus replication, weight loss and death when challenged with the low virus dose (Figure 4). The rate at which mice in the Ad-NPₓ-immunized group lost weight was similar to that
of naïve and Ad-NP\textsubscript{A} immunized mice, and as observed when the Ad-NP\textsubscript{A} mice were challenged with a higher dose of instilled PR8, all mice in this group died by day 8 post-challenge. In contrast, although there was variability in the weight loss for Ad-M2-immunized mice, the average percent weight loss was less after challenge with the low dose compared with the higher dose (Figure 4B vs Figure 2A), and all mice survived (Figure 4C vs Figure 3A). This result demonstrates that M2-mediated immune protection against instilled virus is dependent on the dose of virus inoculated. Clearly the effectiveness of M2 and NP-specific immunity, but not HA-specific immunity, is compromised when mice are challenged by instillation. We therefore predict that instillation impacts the environment in the lower respiratory tract, influencing the function of some immune mechanisms. This appears to correlate with the type of immunity that contributes to protection: HA-specific antibodies induced by Ad-HA protected against both inhalation and instillation challenge, while M2-specific antibodies that rely on NK cells to kill infected cells provided protection against infection that was dependent on the challenge dose, and NP-specific CD8\textsuperscript{+} T cells, the effector cells induced by Ad-NP\textsubscript{A}-immunization, provided some protection against inhaled but not instilled virus challenge. This suggests that for the immunization regimen we have used, antibody-mediated immunity is effective regardless of challenge method, while cell-mediated immunity is more effective against virus that is inhaled than instilled into the lungs.

Challenge by inhalation of very small virus-containing aerosol particles has a lower LD\textsubscript{50} dose [26] and therefore a simple explanation for the difference in protection was that a smaller number of virions enter the lower respiratory tract of mice inhaling virus than in mice exposed to instilled virus. We tested this idea by inoculating mice with 10-fold less instilled virus. Our results showed this was not the case - mice immunized with Ad-NP\textsubscript{A} were
not protected against challenge with the equivalent number of inhaled and instilled virus particles.

Our results are reflective of published reports showing that vaccination strategies eliciting influenza virus-specific CD8+ T cells do not protect mice against intranasal challenge with a virus suspension [32], even though activated CD8+ T cells are capable of protecting mice when transferred directly to the lung [33]. A number of reasons have been proposed for this discrepancy [32], one being that compared to transfer of influenza-specific effector T cells, few influenza-specific CD8+ T cells traffic to the lung. Our findings of protection against inhaled, but not instilled PR8 in Ad-NP\textsubscript{A}-vaccinated mice suggests that the milieu in the lower respiratory tract is dependent on the method of challenge, with recruitment and/or effector function of CD8+ T cells supported when aerosolized virus, but not a liquid suspension, is used to challenge the mice. We propose that this is potentially due to a difference in the chemokine gradient needed for recruitment of NK and CD8+ T cells. It is feasible that the liquid instilled into the lower respiratory tract during challenge prevents establishment of the optimal chemokine gradients by direct dilution of these soluble mediators, or alternatively, activation of physiologic responses such as beating of cilia or secretion of mucins remove chemokines or prevent effective contact between T cells and the infected epithelium. The hypothesis that instillation disrupts chemokine gradients could be tested by comparing the concentrations of these soluble factors in vivo, and measuring the kinetics or magnitude of NK or T cell recruitment to the infected lung.

While a difference in chemokine gradient provides a potential reason for cell-mediated protection against inhaled but not instilled virus, there are other explanations to consider. For example, differences in the cell-types infected or innate mechanisms activated may result in more effective clearance of inhaled than instilled virus by influenza-specific CD8+ T cells. Future experiments should therefore examine the histopathology of lungs from infected mice to determine the number and types of inflammatory cells recruited to the lungs, and to compare extent of infection, cell types infected, and cellular damage as viral or immune pathology could also contribute to the differences in protection against instilled and inhaled virus. Other factors that warrant testing include the potential impact of isoflurane on instilled virus infectivity and function of responding cells [34], and possible differences in immune responses induced in the upper respiratory tract by instilled and inhaled virus. Further experiments are clearly needed to identify the reasons for the difference in Ad-NP\textsubscript{A}-induced protection against instilled and inhaled virus.

Our results show that mice were fully protected against lethal PR8 challenge by prior exposure to the heterosubtypic virus, X31. While antibodies contribute to cross-protection [30], cell-mediated immunity plays a significant role in immunity with large numbers of memory NP-specific CD8+ T cells recruited to the lungs [35]. Our results showing ineffective protection of Ad-NP-immunized mice against instilled virus in our model using a single vaccine dose suggest that the NP-specific immune response, and possible also protection against instilled virus, could be improved by
administration of additional doses or in combination with adjuvant.

In summary, we compared protection against inhaled and instilled virus in mice previously exposed to homologous and heterosubtypic virus, or previously immunized with recombinant adenoviruses expressing HA, M2 or NP. Our results show similar protection against inhaled and instilled challenge for mice that were previously infected or vaccinated with Ad-HA, but not for mice immunized with Ad-M2 or Ad-NP. In these latter groups, there was significant protection against inhaled, but not instilled PR8. These results suggest immune mechanisms often characterized as weak, such as NK or CD8+ T cell-mediated killers, may play a more significant role in protecting against disease and death than previously suggested from studies in which mice were challenged by instillation of a liquid virus suspension. Our data suggest that animal models using aerosol challenge may be a suitable approach to evaluate the potential efficacy of influenza vaccines for which cell-mediated responses are the correlate of immunity.

Methods and materials

Virus and vaccine preparations

A/PR/8/34 (H1N1) and A/HK/68 x 31 (H3N2, X31) virus stocks were prepared by inoculating 9-11 day old embryonated chicken eggs. The allantoic fluid was harvested 60-72 hr post-inoculation, cell debris removed by centrifugation and aliquots stored at -80°C until further use. Infectious titer of each stock was determined by titration on MDCK cells in a standard TCID_{50} assay as previously described [36]. Mice were rendered immune to the challenge virus (positive control) by immunization with a sublethal dose of live virus, with intranasal delivery under isoflurane anesthesia. Mice were immunized with individual influenza proteins using recombinant adenoviruses (rAd) that were administered intramuscularly (50 μl containing 10^{10} virus particles). The Ad5-ΔE1ΔE3 vector was used to express HA (rAd-HA), M2 (rAd-M2) and NP (rAd-NP). rAd-M2 was kindly provided by Dr Suzanne Epstein (CBER, FDA), and rAd expressing nucleoprotein (NP) was kindly provided by Dr Gary Nabel (VRC, NIH). The rAd-NP vector construct induces NP-specific CD8+ T cells in BALB/c mice [5,9]. The HA gene of PR8 was amplified using primers Hind III-H1 and Bam HI-H1, and the Hind III/Bam HI product inserted into pVQpacAd5CMVK-NpA (ViraQuest, North Liberty, IA). The construct was used to generate rAd expressing HA, by transfecting the construct into human embryonic kidney 293 cells that stably express E1A and E1B genes. Bulk rAd stocks were produced by ViraQuest, Inc. The recombinant adenovirus vectors expressing influenza A NP and consensus M2 that we used in our study have been described previously [8,9]. All virus stocks were stored in aliquots at -80°C.

Mice and study design

Female BALB/c mice were purchased from The Jackson Laboratories (Bar Harbor, ME) and housed at Center for Biologics Evaluation and Research (CBER) where they were immunized. Mice that were subjected to nose-only inhalation challenge were shipped to Southern Research Institute (SR, Birmingham, AL) approximately 1 week before the start of the study. Cage size and animal care conformed to the guidelines prescribed in the Guide for the Care and Use of Laboratory Animals, the U.S. Department of Agriculture through the Animal Welfare Act.

Mice were challenged by instillation at CBER, and nose-only inhalation at SR. All experiments were performed under protocols 2006-22 and 10-217 approved by the Institutional Animal Care and Use Committees at CBER and SR, respectively. The mice were approximately 15 weeks of age and weighed between 19 and 26 grams at the time of virus challenge by inhalation or instillation.

Inhalation challenge system

The murine inhalation challenge system consisted of six components: a compressed air source, a bioaerosol delivery line, a 24-port radial nose-only inhalation challenge plenum, a bioaerosol characterization platform, an air handling station, and an exhaust platform. The bioaerosol delivery line consisted of a Collison 3-Jet Nebulizer (BG1 Inc., Waltham, MA), a radial inline aerosol mixer (In-Tox Products, LLC; Albuquerque, NM), and a filtered air passive dilutor. The radial nose-only inhalation challenge plenum (In-Tox Products) was fitted with Positive Flow-By™ restraint tubes (In-Tox Products) and isoaxial sample collection ports that interfaced with the bioaerosol characterization platform.

The bioaerosol characterization platform included air sampling impingers, Model 7541 (Ace Glass, Inc., Vineland, NJ), and an Aerosol Particle Sizer™ Spectrometer (APS, TSI Inc., Shoreview, MN). The air handling station interfaced with the bioaerosol delivery line, the bioaerosol characterization platform, and the exhaust platform and consisted of computer regulated gas flow and pressure controllers (Alicat Scientific, Inc., Tucson, AZ). The exhaust platform consisted of HEPA filters, a differential pressure magnehelic, and a vacuum pump. The bioaerosol delivery line, inhalation challenge plenum, and bioaerosol characterization platform were placed inside a SterilGARD™ III Advance™ (Baker Company; Sanford, ME) biological safety cabinet (BSC). The inhalation challenge plenum was maintained at a slightly negative pressure relative to the BSC. The BSC was maintained at a slightly negative pressure with respect to the Animal Biosafety Level-2 laboratory. Temperature and relative humidity within the inhalation challenge plenum were monitored using a Humidity Temperature Meter (Omega Engineering, Stamford, CT). Inhalation challenge
plenum oxygen levels were monitored continuously during all challenges with a Model 5800 Intelligent Oxygen Monitor (Hudson RCI, Durham, NC).

Prior to conducting inhalation challenges, the system was characterized using PR8 virus [26]. Characterization included achieving and maintaining a target range of aerosol concentrations as determined by plaque assay analysis of impinger samples, and the demonstration of the aerosol particle size distribution of the challenge aerosol determined by APS analysis.

Virus challenge

Inhalation of virus: On three consecutive days prior to inhalation challenge, mice were trained in the nose-only inhalation restraint tubes. On the day of challenge, a Collison 3-Jet Nebulizer was filled with virus stock suspension and connected to the bioaerosol delivery line. The dilution of virus needed to deliver 100 LD₅₀ had previously been determined [26]. A pre-spray nebulizer suspension sample was collected to confirm that the correct virus dilution had been prepared. Mice were placed in nose-only restraint tubes and connected to the inhalation challenge plenum using Positive Flow-By™ nose cones (In-Tox Products, LLC; Albuquerque, NM). Groups of mice were exposed to nebulized virus for 30 minutes. The start of the challenge period (T = 0) began once the nebulizer was activated and set at 30 psi. Inhaled dose (approximately 870 PFU) was calculated as the product of aerosol concentration, murine minute ventilation (0.062 L/min [37]), and challenge duration.

Instillation of virus: Groups of mice were anesthetized by exposure to 3% isoflurane in the presence of 3% O₂ and then inoculated with 30 μl of PR8 diluted in PBS (approximately 5,160 PFU), by applying droplets of the suspension to both nares.

All mice were observed twice daily during quarantine and study periods for signs of morbidity and mortality. Body weights were recorded daily. Animals that had lost ≥25% of their starting weight were euthanized. These mice were moribund, with hunched posture, inactivity and no response to handling. Survival curves were plotted taking into account both euthanized and animals found dead.

Statistical analyses

Statistical analyses for body weight data were performed using the ProVants automated data collection system (Instem; Staffordshire, UK). Differences in weight between groups were determined by two-way repeated measures ANOVA (Microsoft Excel 2003, Redmond, WA) and differences in survival were determined by log-rank Mantel-Cox test using GraphPad PRISM 5 software. The mean, standard deviation, and coefficient of variance were calculated for aerobiology data using Excel or SigmaPlot (Systat Software, Inc., San Jose, CA) when appropriate.

Virus titration

The 50% tissue culture infectious dose (TCID₅₀) was determined by titration on MDCK cells (ATCC line CCL-34) following a standard procedure that was previously described [36]. Briefly, serial ten-fold dilutions of each lung homogenate were inoculated into quadruplicate wells of a 96-well plate containing a monolayer of MDCK cells. After 1 h in a CO₂ incubator at 37°C, an equal volume of serum-free medium containing 3% BSA and TPCK-treated trypsin (5 μg/ml) was added. After 3 days incubation, the remaining cells were stained with crystal violet in glacial acetic acid. The TCID₅₀ titer was defined as the inverse of the dilution that showed cytopathic effect in 50% of the wells.

Abbreviations

TCID₅₀: 50% tissue culture infectious dose; HA: Hemagglutinin; NA: Neuraminidase; M: Matrix; NP: Nucleoprotein; Ad: Adenovirus; LD₅₀: 50% lethal dose; CBER: Center for Biologics Evaluation and Research.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MCE designed and supervised experiments, KR prepared virus stocks, vaccinated mice, and performed instillation challenge experiments; LEB developed aerosol challenge method and supervised inhalation experiments; KY assisted with mouse experiments and performed virus titrations; JG vaccinated mice, and performed instillation challenge experiments; MCE wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank the animal caretakers and facility management for excellent animal care at CBER and Southern Research. We also thank Jeremy Boydston, and Shixiong Li for excellent technical assistance, and Clement Meseda and Ewan Plant for critical reading of our manuscript. CBER PanFlu funds supported work done under contract HHSF223201011220P at Southern Research and all experiments performed at CBER. KY was supported by training funds administered by the Oak Ridge Institute for Science and Education.

Author details

1Division of Vital Products, OVR, CBER, FDA, 8800 Rockville Pike, Building 29A 1D24, Bethesda, MD 20892, USA. 2Southern Research Institute, Birmingham, AL 35205, USA. 3Current address: Alion Science and Technology, NIEHS Inhalation Toxicology Facility, 5 Triangle Drive, P.O. Box 12313, Durham, NC 27709, USA.

Received: 9 February 2013 Accepted: 11 June 2013 Published: 19 June 2013

References

1. Duchuff J, Plotkin J, Vboud C, Earn DJD, Simonsen L: Mortality due to influenza in the United States—an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006, 163:181–187.
2. Osterholm MT: Preparing for the next pandemic. N Engl J Med 2005, 352:1839–1842.
3. Couch RB, Artor RL, Franco LM, Quarles JM, Wells J, Arden N, Nino D, Belmont JM: Antibody correlates and predictors of immunity to naturally-occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013, 207:974–981.
4. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tarn JS, Rappaport R, Eidridge JH, Gruber WC: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042–1053.
1. Epstein SL, Kong WP, Misplon JA, Lo CY, Tunpey TM, Xu L, Nabel GJ: Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404–5410.

2. Price GE, Soboleski MR, Lo CY, Misplon JA, Quiaron MR, Housey KV, Pearce MB, Pappas C, Tunpey TM, Epstein SL: Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010, 5:e13162.

3. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Housey KV, Tunpey TM, Epstein SL: Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512–6521.

4. Soboleski MR, Gabbarb JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL: Cold-adapted influenza and recombinant adeno-virus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 2011, 6:e21937.

5. Epstein SL, Kong WP, Misplon JA, Lo CY, Tunpey TM, Xu L, Nabel GJ: Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404–5410.

6. Price GE, Soboleski MR, Lo CY, Misplon JA, Quiaron MR, Housey KV, Pearce MB, Pappas C, Cappuccini M, Housey KV, Tunpey TM, Epstein SL: Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010, 5:e13162.

7. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Housey KV, Tunpey TM, Epstein SL: Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512–6521.

8. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL: Cold-adapted influenza and recombinant adeno-virus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 2011, 6:e21937.

9. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tunpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426–435.

10. Jegelkaebner A, Schmitz N, Stomri T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598–5605.

11. Stein-Streilein J, Bennett M, Mann D, Kumar V: Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J Immunol 1983, 131:2709–2714.

12. Ely KH, Cookerham T, Roberts AD, Woodland DL: Memory T cell populations in the lung airways are maintained by continual recruitment. J Immunol 2006, 176:537–543.

13. Morris MA, Ley K: Trafficking of natural killer cells. Curr Mol Med 2004, 4:431–438.

14. Verbrist KC, Cole CJ, Field MB, Klonowski KD: A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection. J Immunol 2006, 176:537–543.

15. Eichelberger MC, Green MD: Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines. Expert Opin Drug Metab Toxicol 2011, 7:111–117.

16. Tripp RA, Tompkins SM: Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009, 333:397–412.

17. Bodewes R, Rimmelzawaan GF, Oosterhaus AD: Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010, 9:59–72.

18. Jefferson T, Foxke R, Del Mar C, Dooley L, Feroni E, Hewak B, Prabhala A, Nair S, Rivetti A: Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane Rev J Evidence-based Child Health 2008, 3:951–1013.

19. Tellier R: Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006, 12:1557–1562.

20. Tellier R: Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interf 2009, 6:5783–790.

21. Scott GH, Sydskis R: Responses of mice immunized with influenza virus by aerosol and parental routes. Infect Immun 1976, 13:696–703.

22. Knight V: Viruses as agents of airborne contagion. Ann N Y Acad Sci 1980, 353:147–156.

23. Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA: Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol 2011, 24:131–142.

24. Frankova V: Inhalatory infection of mice with influenza A0/PR8 virus I. The site of primary virus replication and its spread in the respiratory tract. Acta Vet 1975, 19:29–34.

25. Lednicky JA, Hamilton SB, Tuttle RS, Sosa WA, Daniels DE, Swanye DE: Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J 2010, 7:231.

26. Bowen LE, Rivers K, Trombley JE, Boahannon JK, Li SX, Boydston JA, Eichelberger MC: Development of a murine nose-only inhalation model of influenza: comparison of disease caused by instilled and inhaled A/PR8/83. Front Cell Infect Microbiol 2012, 2:712.

27. Larson EW, Dominik JW, Rowberg AH, Higbee GA: Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect Immun 1976, 13:438–447.

28. Misplon JA, Lo CY, Gabbarb JD, Tompkins SM, Epstein SL: Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28:5817–5827.